Showing 1 - 10 of 859
Persistent link: https://www.econbiz.de/10003931919
This article examines a sample of German pharmaceutical firms to highlight the strategic reasons why firms participate in various intellectual property (IP) marketplaces, both proprietary (patents and copyrights) and non-proprietary (open source and non-patented technology). The obstacles that...
Persistent link: https://www.econbiz.de/10009659550
Persistent link: https://www.econbiz.de/10012621329
TRIPs agreement, as this seems to conflict with their own developmental needs. As the following article points out, there …
Persistent link: https://www.econbiz.de/10011548404
Persistent link: https://www.econbiz.de/10001178028
exclusivity for pharmaceuticals products and evaluates safeguards against such evergreening. …
Persistent link: https://www.econbiz.de/10011311672
This article discusses the medical/therapeutical responses to the COVID-19 pandemic and their political economy context. First, the very quick development of several vaccines highlights the richness of the basic knowledge waiting for therapeutical exploitation. Such knowledge has largely...
Persistent link: https://www.econbiz.de/10012803399
Persistent link: https://www.econbiz.de/10011549741
Persistent link: https://www.econbiz.de/10003222862
Persistent link: https://www.econbiz.de/10003222868